Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 4
4(80.0%)
N/A
1(20.0%)
5Total
Phase 4(4)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06228092Phase 4Completed

Neostigmine/Glyco-pyrrolate 50 Mikrogram/kg or Sugammadex 2 mg/kg for Reversal of Neuromuscular Blockade in Elderly Patients

Role: lead

NCT06406010Phase 4Recruiting

Investigating the Effect of Pericapsular Nerve Group (PENG) Block on Postoperative Pain After Peri-acetabular Osteotomy

Role: lead

NCT06409260Not ApplicableRecruiting

Neuromuscular Monitoring in Children (6 Months - 2 Years) With Electromyography and Acceleromyography

Role: lead

NCT06681662Phase 4Recruiting

Ephedrine for Reducing Onset Time of Rocurinium in Elderly Patients

Role: lead

NCT04868409Phase 4Completed

Intubating Conditions During Rapid Sequence Induction in Elderly With Either Suxamethonium 1.0 mg/kg or Rocuronium 1.0 mg/kg

Role: lead

NCT05558137Completed

Mivacurium 0.2 mg/kg in Young (18 - 40 Years) and Elderly (= 80 Years) Patients

Role: lead

NCT04921735Completed

An Observational Study of Cisatracurium 0.15 mg/kg in Young and Elderly (≥ 80 Years) Patients.

Role: lead

All 7 trials loaded